Search Results - "Maughan, B L"

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) vs. EZ alone in metastatic castration refractory prostate cancer (mCRPC) by Maughan, B.L., Hahn, A., Hoffman, J., Morton, K., Gupta, S., Batten, J., Thorley, J., Hawks, J., Nachaegari, G., Nussenzveig, R., Boucher, K., Agarwal, N.

Get full text

Prevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC) by Hahn, A.W., Kapron, A.L., Boyle, J., Kohlmann, W., Poole, A., Gill, D.M., Greenberg, S., Hale, P., Teerlink, C., Maughan, B.L., Cannon-Albright, L., Agarwal, N., Cooney, K.A.

Get full text

943PMolecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS) by Sacristan Santos, V, Esther, J, Maughan, B L, Wesolowski, S, Lin, E, Hahn, A, Sirohi, D, Rathi, N, Swami, U, Nussenzveig, R, Agarwal, N

“…Abstract Background Even though smoking is one of the most recognized risk factors, NS also develop mUC. Identifying molecular drivers of disease progression…”
Get full text

825PRandomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) vs. EZ alone in metastatic castration refractory prostate cancer (mCRPC) by Maughan, B L, Hahn, A, Hoffman, J, Morton, K, Gupta, S, Batten, J, Thorley, J, Hawks, J, Nachaegari, G, Nussenzveig, R, Boucher, K, Agarwal, N

Get full text

Re: Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression across the Germ Cell Malignancy Spectrum by Richie, Jerome P

Get full text

841PPrevalence of clinically actionable germline pathogenic variants (PVs) in advanced prostate cancer (aPC) by Hahn, A W, Kapron, A L, Boyle, J, Kohlmann, W, Poole, A, Gill, D M, Greenberg, S, Hale, P, Teerlink, C, Maughan, B L, Cannon-Albright, L, Agarwal, N, Cooney, K A

Get full text

845PDCDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors by Antonarakis, E S, Velho, P Isaacsson, Agarwal, N, Santos, V Sacristan, Maughan, B L, Pili, R, Adra, N, Sternberg, C N, Vlachostergios, P J, Tagawa, S T, Bryce, A H, McNatty, A L, Reichert, Z R, Dreicer, R, Sartor, O, Lotan, T L, Hussain, M

“…Abstract Background Although once considered a homologous recombination DNA repair gene, CDK12 is now thought to have a distinct role in maintaining genomic…”
Get full text

Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma by Rathi, Nityam, Maughan, Benjamin L, Agarwal, Neeraj, Swami, Umang

“…Cabozantinib is an oral, tyrosine-kinase inhibitor with potent activity against VEGFR2 and MET, along with multiple other tyrosine kinases involved in cancer…”
Get full text

Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities by Sirohi, Deepika, Smith, Steven C, Agarwal, Neeraj, Maughan, Benjamin L

“…Over the past few decades, the classification system of renal cell carcinoma (RCC) variants has witnessed tremendous and ongoing refinement driven by genomic…”
Get full text